Displaying 667 (all) recruiting clinical trials.
-
Technical Development and Optimization for Random Matrix Theory-Based Magnetic Resonance Imaging
The objective of this study is to develop new image reconstruction methods, sequences and postprocessing methods based on random-matrix-theory noise removal, for use in up ...Phase N/A
Non-Interventional
-
Impact of Weight Loss in Patients with Hypertrophic Cardiomyopathy
This is an observational imaging study to evaluate the cardiac effects of weight loss in obese patients with a BMI >=30 with a confirmed diagnosis ...Phase N/A Non-Interventional
-
Gut microbiome alterations as a mechanism of immune dysregulation in new-onset refractory status epilepticus (NORSE)
We will perform a prospective, observational cohort study, with biospecimen collection, of NORSE subjects and subjects with status epilepticus of known cause (e.g. epilepsy ...Phase N/A Non-Interventional
-
Gut Microbiome in Food Protein-Induced Enterocolitis Syndrome: An Observational Study
Food protein-induced enterocolitis syndrome (FPIES) is a non IgE-mediated food allergy that manifests with predominantly gastrointestinal symptoms and usually starts in the first year of ...Phase N/A Non-Interventional
-
NEW YORK OSTEOARTHRITIS HAND COHORT
This is an observational, longitudinal registry of patients with hand osteoarthritis (HOA) that broadly aims to assess the clinical spectrum, risk factors, and identify possible ...Phase N/A Non-Interventional
-
Platelet and Endothelial Dysfunction in Psoriasis
Background: Psoriasis is a common chronic inflammatory skin disease associated with an ~50% increased risk of cardiovascular disease (CVD) compared to matched controls. The influence ...Phase N/A Non-Interventional
-
Investigating auditory processing in the users of auditory brainstem and cochlear implants
This is a basic investigational research study conducted with hearing impaired adults and children who use cochlear implant or auditory brainstem implant (ABI) devices. The ...Phase N/A Non-Interventional
-
A Phase 1b Study of Nivolumab in Patients with Autoimmune Disorders and Advanced Malignancies (AIM-NIVO)
Nivolumab will be investigated at the Food and Drug Administration (FDA)-approved dose of 480 mg intravenous (IV) every 4 weeks until unacceptable toxicity, disease ...Phase
Interventional
-
ACNS1831: A Phase 3 Randomized Study of Selumetinib (IND # 77782) versus Carboplatin/Vincristine in Newly Diagnosed or Previously Untreated Neurofibromatosis Type 1 (NF1) Associated Low-Grade Glioma (LGG)
Low-grade gliomas (LGG) are the most common central nervous system (CNS) tumors in the pediatric population. Although the etiology of most childhood LGG is unknown ...Phase
Interventional
-
Expanded Access to ONC201 for Patients with H3 K27M-mutant and/or Midline Gliomas
This is an intermediate-size expanded access protocol to provide ONC201 to patients with H3 K27M-mutant and/or midline gliomas who cannot access ONC201 through clinical ...Phase N/A Interventional
